Patents by Inventor Rudolf Hauptmann
Rudolf Hauptmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8193188Abstract: Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, R3, R4 and R5 may have the meanings given in the claims and specification.Type: GrantFiled: October 14, 2009Date of Patent: June 5, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Matthias Hoffmann, Matthias Grauert, Trixi Brandl, Martin Steegmaier, Rudolf Hauptmann
-
Patent number: 7989474Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.Type: GrantFiled: December 12, 2008Date of Patent: August 2, 2011Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Gerald Juergen Roth, Armin Heckel, Rainer Walter, Frank Hilberg, Rudolf Hauptmann, Martin Fredrich Stefanic, Florian Colbatzky, Steffan Ernest
-
Publication number: 20110086842Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.Type: ApplicationFiled: December 20, 2010Publication date: April 14, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Heinz STADTMUELLER, Harald ENGELHARDT, Martin STEEGMAIER, Anke BAUM, Ulrich GUERTLER, Andreas SCHOOP, Jens Juergen QUANT, Flavio SOLCA, Rudolf HAUPTMANN, Ulrich REISER, Stephan Karl ZAHN, Lars HERFURTH
-
Publication number: 20100029642Abstract: Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, R3, R4 and R5 may have the meanings given in the claims and specification.Type: ApplicationFiled: October 14, 2009Publication date: February 4, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Matthias HOFFMANN, Matthias GRAUERT, Trixi BRANDL, Martin STEEGMAIER, Rudolf HAUPTMANN
-
Publication number: 20090306104Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.Type: ApplicationFiled: August 16, 2009Publication date: December 10, 2009Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Gerald Juergen Roth, Armin Heckel, Rainer Walter, Frank Hilberg, Rudolf Hauptmann, Martin Fredrich Stefanic, Florian Colbatzky, Steffan Ernest
-
Patent number: 7625899Abstract: Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, R3, R4 and R5 may have the meanings given in the claims and specification.Type: GrantFiled: July 7, 2005Date of Patent: December 1, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Matthias Hoffmann, Matthias Grauert, Trixi Brandl, Martin Steegmaier, Rudolf Hauptmann
-
Publication number: 20090163465Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.Type: ApplicationFiled: February 5, 2009Publication date: June 25, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Heinz STADTMUELLER, Harald ENGELHARDT, Martin STEEGMAIER, Anke BAUM, Ulrich GUERTLER, Andreas SCHOOP, Jens Juergen QUANT, Flavio SOLCA, Rudolf HAUPTMANN, Ulrich REISER, Stephan Karl ZAHN, Lars HERFURTH
-
Publication number: 20090149438Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.Type: ApplicationFiled: February 5, 2009Publication date: June 11, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Heinz STADTMUELLER, Harald ENGELHARDT, Martin STEEGMAIER, Anke BAUM, Ulrich GUERTLER, Andreas SCHOOP, Jens Juergen QUANT, Flavio SOLCA, Rudolf HAUPTMANN, Ulrich REISER, Stephan Karl ZAHN, Lars HERFURTH
-
Patent number: 7521457Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.Type: GrantFiled: August 17, 2005Date of Patent: April 21, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Heinz Stadtmueller, Harald Engelhardt, Martin Steegmaier, Anke Baum, Ulrich Guertler, Andreas Schoop, Jens Juergen Quant, Flavio Solca, Rudolf Hauptmann, Ulrich Reiser, Stephan Karl Zahn, Lars Herfurth
-
Publication number: 20090087405Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.Type: ApplicationFiled: December 12, 2008Publication date: April 2, 2009Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Gerald Juergen ROTH, Armin HECKEL, Rainer WALTER, Frank HILBERG, Rudolf HAUPTMANN, Martin Friedrich STEFANIC, Florian COLBATZKY, Steffen ERNST
-
Patent number: 7282483Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: July 3, 2001Date of Patent: October 16, 2007Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 7264944Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: March 15, 2000Date of Patent: September 4, 2007Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 7241769Abstract: The present invention comprises compounds of general formula (1) wherein A, X, Y, Z, Ra, Rb, Rc, R1, R2 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.Type: GrantFiled: May 18, 2005Date of Patent: July 10, 2007Assignee: Boehringer Ingelheim International GmbHInventors: Heinz Stadtmueller, Harald Engelhardt, Ulrich Reiser, Stephan Karl Zahn, Rudolf Hauptmann, Martin Steegmaier, Ulrich Guertler, Matthias Hoffmann, Matthias Grauert
-
Patent number: 7238776Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: July 3, 2001Date of Patent: July 3, 2007Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Publication number: 20060148800Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.Type: ApplicationFiled: August 17, 2005Publication date: July 6, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Heinz Stadtmueller, Harald Engelhardt, Martin Steegmaier, Anke Baum, Ulrich Guertler, Andreas Schoop, Jen Quant, Flavio Solca, Rudolf Hauptmann, Ulrich Reiser, Stephan Zahn, Lars Herfurth
-
Publication number: 20060009457Abstract: Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, R3, R4 and R5 may have the meanings given in the claims and specification.Type: ApplicationFiled: July 7, 2005Publication date: January 12, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Matthias Hoffmann, Matthias Grauert, Trixi Brandl, Martin Steegmaier, Rudolf Hauptmann
-
Publication number: 20050261295Abstract: The present invention comprises compounds of general formula (1) wherein A, X, Y, Z, Ra, Rb, Rc, R1, R2 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.Type: ApplicationFiled: May 18, 2005Publication date: November 24, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Heinz Stadtmueller, Harald Engelhardt, Ulrich Reiser, Stephan Zahn, Rudolf Hauptmann, Martin Steegmaier, Ulrich Guertler, Matthias Hoffmann, Matthias Grauert
-
Publication number: 20040204458Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.Type: ApplicationFiled: August 14, 2003Publication date: October 14, 2004Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Gerald Juergen Roth, Armin Heckel, Rainer Walter, Frank Hilberg, Rudolf Hauptmann, Martin Friedrich Stefanic, Florian Colbatzky, Steffen Ernst
-
Publication number: 20020183485Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: ApplicationFiled: February 23, 2001Publication date: December 5, 2002Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Publication number: 20020169118Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: ApplicationFiled: July 3, 2001Publication date: November 14, 2002Applicant: Amgen, Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa